Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia

NCT01972152 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypoglycemia

Interventions

DRUG: G-Pen(TM) 1 mg
DRUG: Lilly Glucagon(TM) 1 mg
DRUG: G-Pen(TM) 0.5 mg

Sponsor

Xeris Pharmaceuticals

Collaborators

[object Object]
[object Object]